17-phenyl trinor Prostaglandin F2α amide (17-phenyl trinor PGF2α amide) is an F-series PG analog in which the C-1 carboxyl group has been modified to an unsubstituted amide. PG esters have been shown to have ocular hypotensive activity. PG N-ethyl amides were recently introduced as alternative PG hypotensive prodrugs. Although it has been claimed that PG amides are not converted to the free acids in vivo, studies have shown that bovine and human corneal tissue converts the amides of various PGs to the free acids with a conversion efficiency of about 10-20% relative to the hydrolysis of isopropyl esters. 17-phenyl trinor PGF2α amide would be expected to show the typical intraocular effects of latanoprost, but with the much slower hydrolysis pharmacokinetics of the PG N-amides.

155205-89-3

C23H33NO4

387.51

17-phenyl trinor Prostaglandin F2α amide;17-phenyl trinor Prostaglandin F2α amide

Ethanol:20 mg/mL
DMF:30 mg/mL
DMSO:20 mg/mL
PBS (pH 7.2):2 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years